Evidence map›Paper›PMID 31096927›Full record

ArticleBMC bioinformatics2019

GenePy - a score for estimating gene pathogenicity in individuals using next-generation sequencing data.

E Mossotto, J J Ashton, L O'Gorman, R J Pengelly, R M Beattie, B D MacArthur, S Ennis

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Identification of genetic biomarkers of blood cholesterol levels using whole gene pathogenicity modelling.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. A gene pathogenicity tool "GenePy" identifies missed biallelic diagnoses in the 100,000 Genomes Project.Genetics in medicine : official journal of the American College of Medical Genetics · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

E MossottoDepartment of Human Genetics and Genomic Medicine, University of Southampton, Southampton, UK. Enrico.Mossotto@soton.ac.uk.ORCID http://orcid.org/0000-0003-3996-3931
J J AshtonDepartment of Human Genetics and Genomic Medicine, University of Southampton, Southampton, UK.
L O'GormanDepartment of Human Genetics and Genomic Medicine, University of Southampton, Southampton, UK.
R J PengellyDepartment of Human Genetics and Genomic Medicine, University of Southampton, Southampton, UK.
R M BeattieDepartment of Paediatric Gastroenterology, Southampton Children's Hospital, Southampton, UK.
B D MacArthurInstitute for Life Sciences, University of Southampton, Southampton, UK.
S EnnisDepartment of Human Genetics and Genomic Medicine, University of Southampton, Southampton, UK.
University of Southampton · GBSouthampton Children's Hospital · GB

Funding

Crohn's in Childhood Research Association NoneHilary Marsden Institute for Life Science Scolarship -
6 · The paper itself

Abstract

backgroundNext-generation sequencing is revolutionising diagnosis and treatment of rare diseases, however its application to understanding common disease aetiology is limited. Rare disease applications binarily attribute genetic change(s) at a single locus to a specific phenotype. In common diseases, where multiple genetic variants within and across genes contribute to disease, binary modelling cannot capture the burden of pathogenicity harboured by an individual across a given gene/pathway. We present GenePy, a novel gene-level scoring system for integration and analysis of next-generation sequencing data on a per-individual basis that transforms NGS data interpretation from variant-level to gene-level. This simple and flexible scoring system is intuitive and amenable to integration for machine learning, network and topological approaches, facilitating the investigation of complex phenotypes.

resultsWhole-exome sequencing data from 508 individuals were used to generate GenePy scores. For each variant a score is calculated incorporating: i) population allele frequency estimates; ii) individual zygosity, determined through standard variant calling pipelines and; iii) any user defined deleteriousness metric to inform on functional impact. GenePy then combines scores generated for all variants observed into a single gene score for each individual. We generated a matrix of ~ 14,000 GenePy scores for all individuals for each of sixteen popular deleteriousness metrics. All per-gene scores are corrected for gene length. The majority of genes generate GenePy scores < 0.01 although individuals harbouring multiple rare highly deleterious mutations can accumulate extremely high GenePy scores. In the absence of a comparator metric, we examine GenePy performance in discriminating genes known to be associated with three common, complex diseases. A Mann-Whitney U test conducted on GenePy scores for this positive control gene in cases versus controls demonstrates markedly more significant results (p = 1.37 × 10

conclusionsPer-gene per-individual GenePy scores are intuitive when assessing genetic variation in individual patients or comparing scores between groups. GenePy outperforms the currently accepted best practice tools for combining common and rare variation. GenePy scores are suitable for downstream data integration with transcriptomic and proteomic data that also report at the gene level.

Indexed as

SoftwareAllelesCohort StudiesDatabases, GeneticExomeExome SequencingGene FrequencyHigh-Throughput Nucleotide SequencingHumansPhenotypePolymorphism, Single NucleotideVirulenceZygoteGene scoreGenome analysisMathematical modellingNext-generation sequencingPathogenicity score

Identifiers

PMID31096927
PMCPMC6524327
OpenAlexW2950549285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.